The Cyclin Dependent Kinase 7 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, and Metabolic Disorders which include the indications Colorectal Cancer, Solid Tumor, Rheumatoid Arthritis, and Pituitary ACTH Hypersecretion (Cushing Disease). It also reviews key players involved in Cyclin Dependent Kinase 7 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 7 pipeline targets constitutes close to 22 molecules. Out of which, approximately 19 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, and Discovery stages are 1, 5, 3, 7, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Cyclin Dependent Kinase 7 overview
Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. It phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. thus regulating cell cycle progression. Upon DNA damage it triggers p53/TP53 activation by phosphorylation but is inactivated in turn by p53/TP53. This feedback loop leads to an arrest of the cell cycle.
For a complete picture of Cyclin Dependent Kinase 7’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
